MA Kuang Healthcare Holding (4139) reported revenue of NT$95.7 million for Oct 2026, +7.3% year on year and +6.0% from the previous month. Revenue for Jan–Oct 2026 was NT$901 million (+1.2% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 76 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$95.7 million | +7.3% | +6.0% |
| Sep 2026 | NT$90.3 million | +2.7% | -3.0% |
| Aug 2026 | NT$93 million | +3.1% | +2.8% |
| Jul 2026 | NT$90.5 million | +6.0% | +1.2% |
| Jun 2026 | NT$89.5 million | -1.4% | -7.1% |
| May 2026 | NT$96.3 million | +6.2% | +5.1% |
| Apr 2026 | NT$91.6 million | -0.5% | +0.2% |
| Mar 2026 | NT$91.5 million | -8.6% | +26.4% |
| Feb 2026 | NT$72.4 million | -15.1% | -19.9% |
| Jan 2026 | NT$90.4 million | +15.2% | -16.8% |
| Dec 2025 | NT$108.6 million | -0.2% | +15.8% |
| Nov 2025 | NT$93.8 million | +2.3% | +5.3% |
| Oct 2025 | NT$89.1 million | -12.6% | +1.4% |
| Sep 2025 | NT$87.9 million | -12.6% | -2.6% |
| Aug 2025 | NT$90.3 million | -10.0% | +5.7% |
| Jul 2025 | NT$85.4 million | -7.7% | -5.8% |
| Jun 2025 | NT$90.7 million | +5.0% | +0.0% |
| May 2025 | NT$90.7 million | +2.8% | -1.5% |
| Apr 2025 | NT$92 million | -5.7% | -8.0% |
| Mar 2025 | NT$100 million | +1.7% | +17.3% |
| Feb 2025 | NT$85.3 million | +22.2% | +8.7% |
| Jan 2025 | NT$78.5 million | -15.1% | -27.9% |
| Dec 2024 | NT$108.9 million | -13.9% | +18.7% |
| Nov 2024 | NT$91.7 million | -6.2% | -10.0% |
| Oct 2024 | NT$102 million | -1.5% | +1.4% |
Jan–Oct 2026 cumulative: NT$901 million (+1.2% YoY)
Other Biotech & Medical companies
Compare with peers: MA Kuang Healthcare Holding vs PEC / MA Kuang Healthcare Holding vs Lotus Pharm / MA Kuang Healthcare Holding vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本公司合併營收數為公司自結數
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16